Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine

Viruses

Barbara Coco¹  Piero Colombatto¹  Maurizia R. Brunetto¹  Ferruccio Bonino² 

[1] Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Department of Medical Specialties, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy;Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy;

关键词: HBV;    chronic hepatitis B;    Interferon-α;    nucleos(t)ide analogues;    antiviral treatment;    HBV functional cure;   

DOI  :  10.3390/v14040701

来源: DOAJ

【 摘 要 】

The currently available antiviral treatments (Peg-Interferon-α and Nucleos(t)ide Analogues, NA) for chronic hepatitis B (CHB) achieve a functional cure (serum HBsAg and HDV-DNA clearance) of HBV infection in a limited number of patients. Nevertheless, the continuous pharmacological suppression of viral replication by NA halts liver disease progression lowering the risk of HCC development and improving the survival. In the near future, to fully exploit the potential of old and new drugs for HBV treatment a personalized approach to the patients will be required according to an accurate definition of their virologic, immunologic and clinical profile.

【 授权许可】

Unknown